AvataCore

BOXED WARNING — Risk of Thyroid C-Cell Tumors

Compounded semaglutide/tirzepatide carries the same boxed warning as FDA-approved formulations. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

See full Safety Information before starting therapy.